2 pieces of news worth reporting:
Pfizer Moves Droloxifene Forward in Osteoporosis & Breast Cancer CP336,156 Completes Phase I in Europe, IND in
United States
SAN DIEGO, July 8 /PRNewswire/ -- Ligand Pharmaceuticals Inc. (Nasdaq:LGND) today announced that Pfizer Inc. (NYSE:PFE) has confirmed the initiation of advanced randomized, double-blind, placebo controlled clinical trials to study the effects of droloxifene in the treatment of osteopenic postmenopausal women and
continues on schedule its Phase III trials for droloxifene in breast cancer. If
Phase III trials are successful, Pfizer says it is on track for New Drug Application (NDA) filings in 1998 and 2002 for droloxifene in breast cancer and osteoporosis, respectively. Additionally, Pfizer
confirmed that CP336,156 is expected to complete Phase I trials during 2Q97 and is scheduled for an investigational new drug application (IND) filing in the United States in June of this year.
biz.yahoo.com
ALRT Announces Oral Panretin Clinical Trials Update - AIDS Malignancy Consortium Advances KS Trial -
biz.yahoo.com
SAN DIEGO, July 8 /PRNewswire/ -- Allergan Ligand Retinoid Therapeutics, Inc. (ALRT) (Nasdaq:ALRI - news) announced today an update on the status of clinical
trials with one of its lead products, Panretin(TM) (9-cis-retinoic acid) Oral capsules. In the areas of Kaposi's sarcoma (KS), psoriasis and myelodysplastic syndrome (MDS),
trials are continuing in view of evidence of significant activity. In
renal cell cancer, non-Hodgkin's lymphoma and multiple myeloma, patient accrual to trials will be discontinued due to insufficient activity, and in proliferative vitreoretinopathy (PVR) due to inability to accrue patients in this small patient population.
Patient accrual continues to clinical studies sponsored by the company of ovarian cancer, acute promyelocytic leukemia (APL) and prostate cancer. Breast cancer, pediatric malignancies and the reversal of
bronchial metaplasia (a premalignant lung condition) studies are being conducted under the sponsorship of the National Cancer Institute and are also continuing patient accrual. |
